California Jury Says J&J (JNJ) Defectively Designed ASR Hip Device
Tweet
Share
E-mailGet Alerts JNJ Hot Sheet
Price: $257.98 +0.39%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +5.4%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +5.4%
Join SI Premium – FREE
Johnson & Johnson (NYSE: JNJ) defectively designed ASR hip device, California jury says. The company recalled 93,000 ASR hips in August 2010 after failures.
This was the first trial of 10,750 lawsuits filed over the ASR hip device.
UPDATE - J&J will pay $8.3 million in damages.
Shares of J&J are up 0.4 percent.
This was the first trial of 10,750 lawsuits filed over the ASR hip device.
UPDATE - J&J will pay $8.3 million in damages.
Shares of J&J are up 0.4 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Johnson & Johnson (JNJ) PT Raised to $300 at TD Cowen
- Apple suing OpenAI over alleged misappropriation of trade secrets
- Digital Brands Group to send compliance demands over stock settlement issues
Create E-mail Alert Related Categories
Insiders' Blog, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
